BTK and B-cell chronic lymphocytic leukemia: Because residual phosphorylation of the downstream PI3K target AKT was observed in ibrutinib-treated CLL cells upon BCR stimulation (Fig. S1, C and D), we next investigated the effects of combined BTK and PI3K inhibition on BCR-induced VLA-4 activation.